OncoMatch/Clinical Trials/NCT06911255
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Is NCT06911255 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Tremelimumab Plus Durvalumab (MEDI4736) for hepatocellular carcinoma (hcc).
Treatment: Tremelimumab Plus Durvalumab (MEDI4736) — Safety and Efficacy Evaluation of Tremelimumab Plus Durvalumab(MEDI4736) in Combination with Concurrent Transarterial Chemoembolization in Unresectable Hepatocellular carcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC B, BCLC C (BCLC)
Barcelona clinic liver cancer (BCLC) staging intermediate (B) stage or BCLC advanced stage (C) HCC with or without minimal extrahepatic disease (single-organ metastasis, ≤5 metastatic lesions).
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti- Cytotoxic T-lymphocyte- associated antigen-4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune pathways, including prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.
Cannot have received: hepatic radiation therapy
Prior hepatic radiation therapy including Total Body Irradiation (TBI) for HCC or other malignancy.
Lab requirements
Blood counts
Hemoglobin ≥9.0 g/dL; ANC ≥1500 per mm3; Platelet count ≥75,000 per mm3
Kidney function
Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine clearance CL>40 mL/min by Cockcroft-Gault formula or by 24-hour urine collection
Liver function
Albumin ≥2.8 g/dL; Serum bilirubin ≤1.5 x institutional ULN (except Gilbert's syndrome); AST/ALT ≤5 x institutional ULN
Adequate normal organ and marrow function as defined below: * Hemoglobin ≥9.0 g/dL * Absolute neutrophil count (ANC) ≥1500 per mm3 * Platelet count ≥75,000 per mm3 * Albumin ≥2.8 g/dL * Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN). (This will not apply to patients with confirmed Gilbert's syndrome...) * AST/ALT ≤5 x institutional ULN * Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine clearance CL>40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify